Effects of nicergoline on rabbit electroretinogram during recovery after ischaemia in light and dark.
Nicergoline is an ergot alkaloid derivative acting as a neuroprotective agent. In the present investigation, b-wave time-course recovery profiles under both light- and dark-adapted conditions, were studied in order to evaluate the possible effectiveness of nicergoline in the protection of the rabbit retina. Retinal ischaemia was induced by bilateral occlusion of common carotid artery in male rabbit of the Dutch strain. Groups of animals were subjected to 15-, 30- and 60-min periods of ischaemia under pentobarbital anaesthesia. Electroretinogram recordings were simultaneously obtained from both eyes, using, as the stimulus, the brightest flash from a stimulator positioned 15 cm in front of each eye. The treatment with nicergoline, administered immediately before the carotid occlusion, induced a significant protection only when the ischaemia seemed to cause retinal damage that the reperfusion alone was not able to recover completely. Nicergoline did not modify the recovery rate after 15-min or 30-min light-adapted and 15-min dark-adapted ischaemia; in these conditions the controls showed a full recovery. After 30-min dark-adapted ischaemia, the maximum recovery of the controls was 82%, and nicergoline significantly improved b-wave amplitude at all time points of reperfusion up to the complete recovery. Rabbit retina was irreversibly damaged by a 60-min ischaemia. In these conditions nicergoline significantly increased the percentage of b-wave recovery both in light- and dark-adapted ERG. Nicergoline, probably on the basis of its metabolic actions, seems to be effective in severe conditions of hypoxia and is more potent in dark than in light-adapted conditions. Its effectiveness in these experimental conditions could be justified by the different oxygen consumption of the photoreceptors in light and dark and the different sensitivity of cones and rods to the ischaemia.
Blasco
G
G
Institute of Ophthalmology, University of Trieste Medical School, Ospedale Maggiore, Italy.
Traversa
U
U
Drago
F
F
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000818:Animals; D004596:Electroretinography / Q000187:drug effects; D007511:Ischemia / Q000188:drug therapy*; D008027:Light; D008297:Male; D009530:Nicergoline / Q000627:therapeutic use*; D010775:Photic Stimulation; D011817:Rabbits; D012160:Retina / Q000187:drug effects*; D012171:Retinal Vessels / Q000187:drug effects*
D000317:Adrenergic alpha-Antagonists; D009530:Nicergoline